<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516447</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-c3-002</org_study_id>
    <nct_id>NCT04516447</nct_id>
  </id_info>
  <brief_title>A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K-Group Beta</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>K-Group Beta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability,&#xD;
      preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in&#xD;
      combination with other drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability,&#xD;
      preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3. This&#xD;
      study consists of 4 cohorts in participants with platinum-resistant ovarian, peritoneal, or&#xD;
      fallopian tube cancer. Each cohort will test a combination of ZN-c3 with either pegylated&#xD;
      liposomal doxorubicin (PLD), carboplatin, paclitaxel, or gemcitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety and tolerability of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through Cycle 1 (cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin or gemcitabine)</time_frame>
    <description>Incidence and severity of dose-limiting toxicities (DLTs) in DLT-evaluable subjects during Cycle 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain estimates of clinical activity by determining the objective response rate (ORR) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Objective response rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain estimates of clinical activity by determining the duration of response (DOR) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Duration of response (DOR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain estimates of clinical activity by determining the progression-free survival (PFS) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Progression-free survival (PFS) as defined by RECIST version 1.1 and clinical criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain estimates of clinical activity by determining the time to CA125 progression of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Time to CA125 progression according to the Gynecologic Cancer Intergroup (GCIG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the plasma pharmacokinetics (PK) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Plasma PK parameters of ZN-c3 (and its potential metabolites as applicable)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To investigate the pharmacodynamics of ZN-c3 on the biological activity of γH2AX</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Biological activity in pre- versus post-dose tumor tissue and hair follicle samples of γH2AX</description>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the pharmacodynamics of ZN-c3 on the biological activity of phosphorylated cyclin-dependent kinase 1 (phospho-CDK1)</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Biological activity in pre- versus post-dose tumor tissue and hair follicle samples of phosphorylated cyclin-dependent kinase 1 (phospho-CDK1)</description>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the pharmacodynamics of ZN-c3 on the biological activity of Ki-67</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Biological activity in pre- versus post-dose tumor tissue and hair follicle samples of Ki-67</description>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the pharmacodynamics of ZN-c3 on Baseline Cyclin E expression</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Including, but not limited to, Baseline Cyclin E expression in pre-dose tumor tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the pharmacodynamics of ZN-c3 on molecular determinants of sensitivity to ZN-c3</measure>
    <time_frame>Through completion, approximately 27 months</time_frame>
    <description>Molecular determinants of sensitivity to ZN-c3 including but not limited to Baseline DNA Damage Repair (DDR) gene mutations, deletions, copy number variations or indices of genetic instability in either tumor tissue or cell-free DNA (cfDNA)</description>
  </other_outcome>
  <other_outcome>
    <measure>To characterize the PK of ZN-c3 in tumor tissue</measure>
    <time_frame>At Cycle 1 Day 1 and Cycle 2 Day 1 (pre-dose) (each cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin or gemcitabine)</time_frame>
    <description>ZN-c3 concentrations (and its potential metabolites as applicable) in tumor tissue</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Combination with carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles, and (2) paclitaxel 80 mg/m^2 administered intravenously over 60 minutes (± 10 minutes) on Days 1, 8, and 15 of each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination with gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles, and (2) gemcitabine 1000 mg/m^2 intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c3</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Combination with PLD</arm_group_label>
    <arm_group_label>Combination with carboplatin</arm_group_label>
    <arm_group_label>Combination with gemcitabine</arm_group_label>
    <arm_group_label>Combination with paclitaxel</arm_group_label>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is an approved drug</description>
    <arm_group_label>Combination with carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>Pegylated liposomal doxorubicin (PLD) is an approved drug</description>
    <arm_group_label>Combination with PLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is an approved drug</description>
    <arm_group_label>Combination with paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is an approved drug</description>
    <arm_group_label>Combination with gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent prior to initiation of any study-related&#xD;
             procedures that are not considered standard of care.&#xD;
&#xD;
          -  Females ≥ 18 years of age or the minimum legal adult age (whichever is greater) at the&#xD;
             time of informed consent.&#xD;
&#xD;
          -  ECOG performance status ≤ 2.&#xD;
&#xD;
          -  Histologically or cytologically confirmed high-grade serous epithelial ovarian&#xD;
             carcinoma, fallopian tube, or peritoneal carcinoma.&#xD;
&#xD;
          -  Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the&#xD;
             metastatic setting.&#xD;
&#xD;
          -  The disease must be platinum-resistant, i.e., the Platinum-Free Interval (PFI) must&#xD;
             have been &lt; 6 months. Platinum refractory disease, i.e., PD during first-line&#xD;
             platinum-based therapy is allowed.&#xD;
&#xD;
          -  Measurable disease per RECIST version 1.1.&#xD;
&#xD;
          -  Adequate hematologic and organ function as defined by the following criteria:&#xD;
&#xD;
               1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily&#xD;
                  administration of filgrastim/sargramostim or within 3 weeks after administration&#xD;
                  of pegfilgrastim.&#xD;
&#xD;
               2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days&#xD;
                  after transfusion of platelets.&#xD;
&#xD;
               3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper&#xD;
                  limit of normal (ULN). If liver function abnormalities are due to underlying&#xD;
                  liver metastases, AST and ALT ≤ 5 x ULN.&#xD;
&#xD;
               4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum beta human&#xD;
             chorionic gonadotropin (β-hCG) test and agree to use an effective method of&#xD;
             contraception per institutional standard.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% or within normal limits of the&#xD;
             institution (only for subjects treated with PLD).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline&#xD;
             ovarian tumor.&#xD;
&#xD;
          -  Any of the following treatment interventions within the specified time frame prior to&#xD;
             Cycle 1 Day 1:&#xD;
&#xD;
               1. Major surgery within 28 days.&#xD;
&#xD;
               2. Radiation therapy within 21 days.&#xD;
&#xD;
               3. Autologous or allogeneic stem cell transplant within 3 months.&#xD;
&#xD;
          -  A serious illness or medical condition(s) including, but not limited to, the&#xD;
             following:&#xD;
&#xD;
               1. Brain metastases that require immediate treatment or are clinically or&#xD;
                  radiologically unstable.&#xD;
&#xD;
               2. Leptomeningeal disease that requires or is anticipated to require immediate&#xD;
                  treatment.&#xD;
&#xD;
               3. Myocardial impairment of any cause.&#xD;
&#xD;
               4. Significant gastrointestinal abnormalities.&#xD;
&#xD;
               5. Active or uncontrolled infection.&#xD;
&#xD;
          -  Unresolved toxicity of Grade &gt; 1 attributed to any prior therapies (excluding Grade 2&#xD;
             neuropathy, alopecia or skin pigmentation).&#xD;
&#xD;
          -  Pregnant or lactating females (including the cessation of lactation) or females of&#xD;
             childbearing potential who have a positive serum pregnancy test within 14 days prior&#xD;
             to Cycle 1 Day 1.&#xD;
&#xD;
          -  Subjects with active (uncontrolled, metastatic) second malignancies or requiring&#xD;
             therapy.&#xD;
&#xD;
          -  12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of&#xD;
             &gt; 480 msec, except for subjects with atrioventricular pacemakers or other conditions&#xD;
             (e.g., right bundle branch block) that render the QT measurement invalid.&#xD;
&#xD;
          -  History or current evidence of congenital long QT syndrome.&#xD;
&#xD;
          -  Taking medications that lead to significant QT prolongation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Pultar, MD</last_name>
    <role>Study Director</role>
    <affiliation>K-Group Beta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Director</last_name>
    <phone>8582634333</phone>
    <email>info@zenopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 0103</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2707</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2708</name>
      <address>
        <city>Sunshine Coast</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2706</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2705</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1001</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1002</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1003</name>
      <address>
        <city>Tuzla</city>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1202</name>
      <address>
        <city>Panagyurishte</city>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1201</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1401</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2903</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2904</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1902</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Korea, Republic of</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

